Arcus Biosciences 관리
관리 기준 확인 2/4
Arcus Biosciences CEO는 Terry Rosen, May2015 에 임명되었습니다 의 임기는 9.5 년입니다. 총 연간 보상은 $ 10.12M, 6.4% 로 구성됩니다. 6.4% 급여 및 93.6% 보너스(회사 주식 및 옵션 포함). 는 $ 53.28M 가치에 해당하는 회사 주식의 4.08% 직접 소유합니다. 53.28M. 경영진과 이사회의 평균 재임 기간은 각각 4.3 년과 4.7 년입니다.
주요 정보
Terry Rosen
최고 경영자
US$10.1m
총 보상
| CEO 급여 비율 | 6.4% |
| CEO 임기 | 9.5yrs |
| CEO 소유권 | 4.1% |
| 경영진 평균 재임 기간 | 4.3yrs |
| 이사회 평균 재임 기간 | 4.7yrs |
최근 관리 업데이트
Recent updates
Arcus Biosciences, Inc.'s (NYSE:RCUS) Price Is Right But Growth Is Lacking
Nov 21
Arcus Biosciences: Advancing On Several Fronts
Oct 29Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones
Sep 23Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 15Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business
Aug 19Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO
May 15Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts
May 13Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money
May 10We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth
Mar 20What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You
Feb 23Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment
Feb 22Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Dec 18Arcus Biosciences: Showing There Might Be Something To TIGIT After All
Dec 15Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?
Nov 30Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey
Nov 20Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data
Aug 29Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation
Aug 08Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates
Jun 15Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk
May 05Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17
Nov 02CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$270m |
| Jun 30 2024 | n/a | n/a | -US$249m |
| Mar 31 2024 | n/a | n/a | -US$231m |
| Dec 31 2023 | US$10m | US$650k | -US$307m |
| Sep 30 2023 | n/a | n/a | -US$293m |
| Jun 30 2023 | n/a | n/a | -US$287m |
| Mar 31 2023 | n/a | n/a | -US$279m |
| Dec 31 2022 | US$9m | US$350k | -US$267m |
| Sep 30 2022 | n/a | n/a | US$80m |
| Jun 30 2022 | n/a | n/a | US$67m |
| Mar 31 2022 | n/a | n/a | US$58m |
| Dec 31 2021 | US$9m | US$367k | US$53m |
| Sep 30 2021 | n/a | n/a | -US$278m |
| Jun 30 2021 | n/a | n/a | -US$199m |
| Mar 31 2021 | n/a | n/a | -US$168m |
| Dec 31 2020 | US$6m | US$326k | -US$123m |
| Sep 30 2020 | n/a | n/a | -US$88m |
| Jun 30 2020 | n/a | n/a | -US$112m |
| Mar 31 2020 | n/a | n/a | -US$95m |
| Dec 31 2019 | US$2m | US$340k | -US$85m |
| Sep 30 2019 | n/a | n/a | -US$80m |
| Jun 30 2019 | n/a | n/a | -US$69m |
| Mar 31 2019 | n/a | n/a | -US$54m |
| Dec 31 2018 | US$1m | US$295k | -US$50m |
| Sep 30 2018 | n/a | n/a | -US$51m |
| Jun 30 2018 | n/a | n/a | -US$63m |
| Mar 31 2018 | n/a | n/a | -US$59m |
| Dec 31 2017 | US$427k | US$315k | -US$53m |
보상 대 시장: Terry 의 총 보상 ($USD 10.12M )은 US 시장( $USD 5.37M ).
보상과 수익: 회사가 수익성이 없는 동안 Terry 의 보상이 증가했습니다.
CEO
Terry Rosen (64 yo)
9.5yrs
테뉴어
US$10,120,945
보상
Dr. Terry J. Rosen, Ph D., serves as Director at PACT Pharma, Inc. He co-founded Arcus Biosciences, Inc. in 2015 and has been its Chief Executive Officer since May 2015. Dr. Rosen has been the Chairman of...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Co-Founder | 9.5yrs | US$10.12m | 4.08% $ 53.3m | |
| Co- Founder & President | 9.5yrs | US$4.75m | 1.56% $ 20.4m | |
| Principal Financial Officer & CFO | 4.3yrs | US$3.59m | 0.017% $ 220.7k | |
| Chief Operating Officer | 4.1yrs | US$4.74m | 0.082% $ 1.1m | |
| Chief Medical Officer | 2.3yrs | US$3.69m | 0.022% $ 288.3k | |
| Co-Founder & Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| VP of Finance & Principal Accounting Officer | 1.7yrs | 데이터 없음 | 0.0032% $ 42.2k | |
| Chief Scientific Officer | 3.8yrs | 데이터 없음 | 데이터 없음 | |
| General Counsel & Corporate Secretary | 6.3yrs | US$2.92m | 0.052% $ 684.1k | |
| Vice President of Corporate Communications | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Human Resources & Operations | no data | 데이터 없음 | 데이터 없음 | |
| Chief Commercial Officer | 5.4yrs | 데이터 없음 | 데이터 없음 |
4.3yrs
평균 재임 기간
52yo
평균 연령
경험이 풍부한 관리: RCUS 의 관리팀은 경험 ( 4.3 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Co-Founder | 9.6yrs | US$10.12m | 4.08% $ 53.3m | |
| Co-Founder & Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Lead Independent Director | 9.5yrs | US$503.21k | 0.16% $ 2.1m | |
| Independent Director | 7.2yrs | US$479.08k | 0.16% $ 2.1m | |
| Independent Director | 3.9yrs | US$455.83k | 0.023% $ 298.9k | |
| Chairman of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 4.9yrs | US$455.83k | 0.018% $ 241.4k | |
| Independent Director & Member of Scientific Advisory Board | 4.5yrs | US$500.83k | 0.054% $ 703.3k | |
| Independent Director & Member of Scientific Advisory Board | 9.8yrs | US$470.83k | 0.033% $ 435.6k | |
| Director | 4.3yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 3.3yrs | US$450.83k | 0.015% $ 200.3k | |
| Member of Scientific Advisory Board | 4.2yrs | 데이터 없음 | 데이터 없음 |
4.7yrs
평균 재임 기간
63.5yo
평균 연령
경험이 풍부한 이사회: RCUS 의 이사회는 경험(평균 재직 기간 4.7 년)으로 간주됩니다.